FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038963010> ?p ?o ?g. }

• W2038963010 endingPage "395" @default.
• W2038963010 startingPage "389" @default.
• W2038963010 abstract "Abstract Objective/Hypothesis : Adenoviral interleukin‐2 (AdV‐IL‐2) gene therapy has previously not proven effective in treating established murine oral cancer. We hypothesize that the intratumoral level of IL‐2 expression is a major limiting factor in treatment outcome. Methods : A microscopic disease and established oral cancer murine model was used to test this hypothesis. IL‐2 gene transfer was performed with a recombinant adenovirus vector. Results : Tumor cells were transduced in vitro with AdV‐IL‐2 and subsequently implanted into the floor of the mouth in C3H/ HeJ mice. IL‐2 expression in vitro ranged from 990 to 1,050 pg/10 6 tumor cells. This microscopic disease treatment resulted in either complete tumor regression or a dramatic decrease in tumor progression. Cytolytic T‐cell (CTL) assays demonstrated a predominance of CD8‐specific, T‐cell–mediated tumor killing. Reducing IL‐2 expression by half with a mixture of 1:1 transduced to nontransduced tumor cells eliminated the antitumor effect and decreased the CTL response. These findings support the presence of a critical “threshold” of IL‐2 expression. Adenovirus repurification and amplification allowed isolation of a twofoldhigher‐titer AdV‐IL‐2 vector. Treatment of established tumors with the higher‐titer AdV‐IL‐2 at a new maximal dose of 1.4 × 10 9 plaque‐forming units (pfu) increased in vivo IL‐2 expression to 1,127 pg/10 6 cells and generated a significant antitumor response. Complete regression of established tumors, however, could not be achieved, and we noted a decrease in IL‐2 expression well below the threshold at 1 week after treatment. Upon repeat maximal AdV‐IL‐2 injection in vivo, a greater antitumor effect and increased CTL response was seen, but also, 28% of the animals died of IL‐2 toxicity. Conclusion : Although limited by expression and toxicity as a single‐treatment strategy for established tumors, AdV‐IL‐2 gene therapy should be considered a potential component of combination therapy strategies." @default.
• W2038963010 created "2016-06-24" @default.
• W2038963010 creator A5010262139 @default.
• W2038963010 creator A5017991749 @default.
• W2038963010 creator A5050378807 @default.
• W2038963010 creator A5057978718 @default.
• W2038963010 creator A5066588608 @default.
• W2038963010 creator A5066707073 @default.
• W2038963010 date "1999-03-01" @default.
• W2038963010 modified "2023-10-10" @default.
• W2038963010 title "Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer" @default.
• W2038963010 cites W1544808474 @default.
• W2038963010 cites W1965995080 @default.
• W2038963010 cites W1979343444 @default.
• W2038963010 cites W1990668606 @default.
• W2038963010 cites W1995289673 @default.
• W2038963010 cites W2002323372 @default.
• W2038963010 cites W2038453307 @default.
• W2038963010 cites W2048331497 @default.
• W2038963010 cites W2051962533 @default.
• W2038963010 cites W2066416111 @default.
• W2038963010 cites W2091691801 @default.
• W2038963010 cites W2091993406 @default.
• W2038963010 cites W2121421904 @default.
• W2038963010 cites W2129859001 @default.
• W2038963010 cites W2322553446 @default.
• W2038963010 cites W2326245275 @default.
• W2038963010 cites W4245034281 @default.
• W2038963010 cites W4255437625 @default.
• W2038963010 doi "https://doi.org/10.1097/00005537-199903000-00009" @default.
• W2038963010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10089963" @default.
• W2038963010 hasPublicationYear "1999" @default.
• W2038963010 type Work @default.
• W2038963010 sameAs 2038963010 @default.
• W2038963010 citedByCount "21" @default.
• W2038963010 crossrefType "journal-article" @default.
• W2038963010 hasAuthorship W2038963010A5010262139 @default.
• W2038963010 hasAuthorship W2038963010A5017991749 @default.
• W2038963010 hasAuthorship W2038963010A5050378807 @default.
• W2038963010 hasAuthorship W2038963010A5057978718 @default.
• W2038963010 hasAuthorship W2038963010A5066588608 @default.
• W2038963010 hasAuthorship W2038963010A5066707073 @default.
• W2038963010 hasConcept C104317684 @default.
• W2038963010 hasConcept C111599444 @default.
• W2038963010 hasConcept C121608353 @default.
• W2038963010 hasConcept C126322002 @default.
• W2038963010 hasConcept C147969180 @default.
• W2038963010 hasConcept C150903083 @default.
• W2038963010 hasConcept C153911025 @default.
• W2038963010 hasConcept C154317977 @default.
• W2038963010 hasConcept C167672396 @default.
• W2038963010 hasConcept C202751555 @default.
• W2038963010 hasConcept C203014093 @default.
• W2038963010 hasConcept C207001950 @default.
• W2038963010 hasConcept C2522874641 @default.
• W2038963010 hasConcept C2776954459 @default.
• W2038963010 hasConcept C2777371288 @default.
• W2038963010 hasConcept C2777701055 @default.
• W2038963010 hasConcept C2778690821 @default.
• W2038963010 hasConcept C32470452 @default.
• W2038963010 hasConcept C32611913 @default.
• W2038963010 hasConcept C40767141 @default.
• W2038963010 hasConcept C502942594 @default.
• W2038963010 hasConcept C55493867 @default.
• W2038963010 hasConcept C71924100 @default.
• W2038963010 hasConcept C86803240 @default.
• W2038963010 hasConcept C8891405 @default.
• W2038963010 hasConceptScore W2038963010C104317684 @default.
• W2038963010 hasConceptScore W2038963010C111599444 @default.
• W2038963010 hasConceptScore W2038963010C121608353 @default.
• W2038963010 hasConceptScore W2038963010C126322002 @default.
• W2038963010 hasConceptScore W2038963010C147969180 @default.
• W2038963010 hasConceptScore W2038963010C150903083 @default.
• W2038963010 hasConceptScore W2038963010C153911025 @default.
• W2038963010 hasConceptScore W2038963010C154317977 @default.
• W2038963010 hasConceptScore W2038963010C167672396 @default.
• W2038963010 hasConceptScore W2038963010C202751555 @default.
• W2038963010 hasConceptScore W2038963010C203014093 @default.
• W2038963010 hasConceptScore W2038963010C207001950 @default.
• W2038963010 hasConceptScore W2038963010C2522874641 @default.
• W2038963010 hasConceptScore W2038963010C2776954459 @default.
• W2038963010 hasConceptScore W2038963010C2777371288 @default.
• W2038963010 hasConceptScore W2038963010C2777701055 @default.
• W2038963010 hasConceptScore W2038963010C2778690821 @default.
• W2038963010 hasConceptScore W2038963010C32470452 @default.
• W2038963010 hasConceptScore W2038963010C32611913 @default.
• W2038963010 hasConceptScore W2038963010C40767141 @default.
• W2038963010 hasConceptScore W2038963010C502942594 @default.
• W2038963010 hasConceptScore W2038963010C55493867 @default.
• W2038963010 hasConceptScore W2038963010C71924100 @default.
• W2038963010 hasConceptScore W2038963010C86803240 @default.
• W2038963010 hasConceptScore W2038963010C8891405 @default.
• W2038963010 hasIssue "3" @default.
• W2038963010 hasLocation W20389630101 @default.
• W2038963010 hasLocation W20389630102 @default.
• W2038963010 hasOpenAccess W2038963010 @default.
• W2038963010 hasPrimaryLocation W20389630101 @default.
• W2038963010 hasRelatedWork W1587611090 @default.

• next